Tech Company M&A Transactions
Igeneon Acquisition
Operating out of Vienna, Igeneon was acquired by Aphton. Financial terms set the valuation at $81 million.
Transaction Overview
Company Name
Acquired By
Announced On
12/15/2004
Transaction Type
M&A
Amount
$81,000,000
M&A Terms
Pursuant to the agreement, Igeneon stockholders will receive 21.5 million shares of Aphton common stock in exchange for 100% of the equity of Igeneon. Based on the closing price of Aphton's common stock on December 14, 2004, the value of the deal would be approximately $81 million.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
Brunner Strasse 69 Obj.3
Vienna, 1230
Austria
Vienna, 1230
Austria
Phone
Website
Email Address
Not Recorded
Overview
Igeneon, is a clinical stage biopharmaceutical company focused on the development of active and passive cancer immunotherapies designed to prevent or delay the development of metastases in cancers of epithelial origin.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/14/2004: TeleCIS Wireless venture capital transaction
Next: 12/15/2004: NDO Surgical venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs